drugset / Trial / NCT04468009

Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma

NCT04468009

Phase 2 Completed 134 enrolled Hospital de Infecciosas Francisco Javier Muniz
RandomizedSequentialOpen-labelTreatment

Summary

This study aims to collect convalescent plasma and use it as experimental treatment in critically ill Covid-19 patients in order to reduce mortality and length of stay in intensive care unit.

Timeline

Start
2020-06-25
Primary completion
2021-01-19
Completion
2021-06-19

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Convalescent Plasma Protein / enzyme biologic

Indications